Dergiler / Turkish Journal of Medical Sciences / 2011 / Cilt: 41 - Sayı: 4

An investigation of the antimicrobial impact of drug combinations against Mycobacterium tuberculosis strains

Sayfa
719–724
Yayın Tarihi
2022-11-04
DOI
—
🏛️Bu makalenin bibliyografik verileri ve tam metin bağlantısı DergiPark üzerinden sağlanmıştır.
DergiPark Kaydı ↗
✨

Yapay Zeka Hızlı Bakış & Çıkarımlar

AI Insight
⚡ TL;DR(1 Cümlede Hızlı Çıkarım)

Conclusion: Although many previous studies have found a synergistic activity with similar drug combinations, only additive interaction was observed in some of the M. tuberculosis strains involved in this study.

📌 3 Maddede Bu Makale

🎯
Amaç & Hipotez:To investigate the in vitro activity of linezolid and ofloxacin in combination with first-line antituberculosis agents (isoniazid and rifampicin) against M. tuberculosis strains.
📊
Temel Bulgular & Veri:Results: A total of 9 M. tuberculosis strains were used in this study, 5 of which were multidrug-resistant (MDR) and 4 of which were not.
💡
Sonuç & Katkı:Conclusion: Although many previous studies have found a synergistic activity with similar drug combinations, only additive interaction was observed in some of the M. tuberculosis strains involved in this study.
🔬Tür:Araştırma Makalesi
📍Kapsam:Genişletilmiş Akademik Örneklem
⚙️Değişkenler:Key words: Mycobacterium tuberculosis · drug combinations · ofloxacin

Özet

To investigate the in vitro activity of linezolid and ofloxacin in combination with first-line antituberculosis agents (isoniazid and rifampicin) against M. tuberculosis strains. The use of combinations that include fluoroquinolones and oxazolidinone is now being considered for the treatment of resistant Mycobacterium tuberculosis strains. Materials and methods: The minimum inhibitory concentrations of the test drugs were determined by the standard agar dilution method. The interaction of drug combinations was investigated by time-kill method. Results: A total of 9 M. tuberculosis strains were used in this study, 5 of which were multidrug-resistant (MDR) and 4 of which were not. The studied 2-agent drug combinations were indifferent in 4 MDR and 2 non-MDR M. tuberculosis strains, respectively. Additive interaction was observed between isoniazid and ofloxacin in one MDR M. tuberculosis strain on the eighth day and in one non-MDR strain on the third, fifth, and eighth days, respectively, while rifampicin and linezolid exhibited additive interaction in another non-MDR strain on the eighth day. Conclusion: Although many previous studies have found a synergistic activity with similar drug combinations, only additive interaction was observed in some of the M. tuberculosis strains involved in this study.

Abstract

To investigate the in vitro activity of linezolid and ofloxacin in combination with first-line antituberculosis agents (isoniazid and rifampicin) against M. tuberculosis strains. The use of combinations that include fluoroquinolones and oxazolidinone is now being considered for the treatment of resistant Mycobacterium tuberculosis strains. Materials and methods: The minimum inhibitory concentrations of the test drugs were determined by the standard agar dilution method. The interaction of drug combinations was investigated by time-kill method. Results: A total of 9 M. tuberculosis strains were used in this study, 5 of which were multidrug-resistant (MDR) and 4 of which were not. The studied 2-agent drug combinations were indifferent in 4 MDR and 2 non-MDR M. tuberculosis strains, respectively. Additive interaction was observed between isoniazid and ofloxacin in one MDR M. tuberculosis strain on the eighth day and in one non-MDR strain on the third, fifth, and eighth days, respectively, while rifampicin and linezolid exhibited additive interaction in another non-MDR strain on the eighth day. Conclusion: Although many previous studies have found a synergistic activity with similar drug combinations, only additive interaction was observed in some of the M. tuberculosis strains involved in this study.

🔖

Bu Makaleye Atıf Yap

TAŞLI, H., HOŞGÖR, M. L., ERAÇ, B., ERMERTCAN, Ş. (2022). An investigation of the antimicrobial impact of drug combinations against Mycobacterium tuberculosis strains. Turkish Journal of Medical Sciences, Cilt: 41 - Sayı: 4, 719–724. https://ajindex.com/articles/611389

📄 Tam Metin PDF Okuyucu

📄

PDF görüntüleyici hazırlanıyor...

Kaynakça (9)

  1. Parreiras PM, Lobato FCF, Alencar AP, Figueiredo T, Gomes HM, Boéchat N et al.Drug susceptibility of Brazilian strains of Mycobacterium bovis using traditional and molecular techniques. Mem Inst Oswaldo Cruz 2004;99: 749-52.
  2. Erturan Z, Uzun M.In vitro activity of linezolid against multidrug-resistant Mycobacterium tuberculosis isolates. Int J Antimicrob Agents 2005;26: 78-80.
  3. Luna-Herrera J, Venkata-Reddy M, Gangadharam PRJ. In vitro activity of the benzoxazinorifamycin KRM-1648 against drug susceptible and multidrug-resistant tubercle bacilli. Antimicrob Agents Chemother 1995; 39: 440-4. 7. Rastogi N, Goh KS, Bryskier A, Devallois A.In vitro activities of levofl oxacin used alone and in combination with fi rst- and second-line antituberculous drugs against Mycobacterium tuberculosis. Antimicrob Agents Chemother 1996;40: 1610-6.
  4. Bozeman L, Burman W, Metchock B, Welch L, Weiner M and the Tuberculosis Trials Consortium. Fluoroquinolone susceptibility among Mycobacterium tuberculosis isolates from the United States and Canada. Clin Infect Dis 2005; 40: 386-91.
  5. Di Peri G, Bonora S.Which agents should we use for the treatment of multidrug-resistant Mycobacterium tuberculosis? J Antimicrob Chemother 2004;54: 593-602. Rodríguez Diaz JC, Ruiz M, López M, Royo G. Synergic activity of fl uoroquinolones and linezolid againstMycobacterium tuberculosis. Int J Antimicrob Agents 2003; 21: 354-6.
  6. Bhusal Y, Shiohira CM, Yamane N. Determination of in vitro synergy when three antimicrobial agents are combined against Mycobacterium tuberculosis. Int J Antimicrob Agents 2005; 26: 292-7. Clinical and Laboratory Standards Institute (National Committee for Clinical Laboratory Standards). Susceptibility testing of mycobacteria, nocardia, and other aerobic actinomycetes, 2nd ed., tentative standard M24-T2. Wayne, PA, USA: NCCLS; 2000.
  7. Yajko DM, Nassos PS, Hadley WK. Th erapeutic implications of inhibition versus killing of Mycobacterium avium complex by antimicrobial agents. Antimicrob Agents Chemother 1987; 31: 117-20. von der Lippe B, Sandven P, Brubak O.Effi cacy and safety of linezolid in multidrug resistant tuberculosis--a report of ten cases. J Infect 2006; 52: 92-6.
  8. Escribano I, Rodríguez JC, Llorca B, Garcia-Pachon E, Ruiz M, Royo G.Importance of the effl ux pump systems in the resistance of Mycobacterium tuberculosis to fl uoroquinolones and linezolid. Chemotherapy 2007;53: 397-401.
  9. Huang TS, Liu YC, Sy CL, Chen YS, Tu HZ, Chen BC.In vitro activities of linezolid against c